KOSDAQRetail & Consumer109960

Aptocrom

₩1,758▲ 2.09%2026-11-18 close
Market Cap
₩26.6B
Turnover
₩5,723,798
Volume
3.3K
Shares out.
15.1M
PER
0.3×
PBR
0.1×
EPS
₩5,368
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Aptocrom: Uneven Quarters After Capital Reduction

Aptocrom's 2025 revenue fell 40.2% and the company slid back into an operating loss, while quarterly operating results and net profit attributable to controlling shareholders have swung sharply in 2026.

  1. 1

    Annual revenue peaked at KRW 16.4 billion in 2024 and fell 40.2% to KRW 9.81 billion in 2025.

  2. 2

    The 2025 operating loss was KRW 2.29 billion and the net loss attributable to controlling shareholders was KRW 5.56 billion, marking two straight years of losses from 2024 to 2025.

  3. 3

    Operating profit turned positive at KRW 80.58 million in the second quarter of 2026, then the third quarter returned to an operating loss of KRW 302 million.

  4. 4

    Net profit attributable to controlling shareholders reached KRW 46.1 billion and KRW 31.5 billion in the second and third quarters of 2026, far above the operating results and pointing to large non-operating items.

  5. 5

    A 20-to-1 free share consolidation was decided in February 2026 and approved at the March shareholder meeting, sharply changing the capital structure.

02

Business structure

Aptocrom was founded in 1998 and listed on KOSDAQ in 2009. It is classified as a specialized wholesale company. Its core business is the distribution and sale of more than 100 pharmaceutical products. The company also runs a leasing business for real estate and equipment.

Through its subsidiary, Aprogen I&C, it designs, builds and installs specialty insulation for nuclear plants and produces FOAMGLAS foam glass insulation. The 2025 revenue decline was attributed to the completion of Shin Hanul Unit 2, which reduced insulation construction revenue.

In pharmaceuticals, competition among wholesalers intensified, and revenue declined even though the company already holds a high market share. Construction at Saeul Units 3 and 4 is ongoing, but construction volume was lower than the prior year in the cumulative period through the third quarter of 2025.

The company renamed itself Aptocrom and added blockchain and virtual asset businesses to its articles of incorporation. As a result, revenue depends simultaneously on large nuclear construction orders and on competition in pharmaceutical wholesale.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.5B-₩400M−16.2%
2025Q4₩2.4B-₩500M−20.9%
2026Q1₩2.4B-₩500M−22.4%
2026Q2₩3.4B₩80,582,3032.4%
2026Q3₩2.8B-₩300M−10.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩9.6B-₩900M-₩5.6B−9.7%−2.8%7.0%
2023₩16B₩200M₩4.3B1.2%1.5%10.2%
2024₩16.4B₩1B-₩28.1B5.9%−9.3%10.9%
2025₩9.8B-₩2.3B-₩5.6B−23.3%−1.8%4.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue rose from KRW 9.6 billion in 2022 to KRW 16 billion in 2023, a 66.8% increase over the prior year, then reached KRW 16.4 billion in 2024, up 2.5%, before falling to KRW 9.81 billion in 2025, down 40.2%. Among 2022 to 2025, the largest year was 2024 and the smallest was 2022.

Operating income moved from an operating loss of KRW 930 million in 2022 to an operating profit of KRW 189 million in 2023, a turn to profit, and KRW 967 million in 2024, up 412.5%.

In 2025 the company posted an operating loss of KRW 2.29 billion, a turn back into the red, and its operating margin of -23.3% was the lowest of the four years.

Net profit attributable to controlling shareholders moved to KRW 4.3 billion in 2023 but posted losses of KRW 28.1 billion in 2024 and KRW 5.56 billion in 2025, two consecutive years of losses from 2024 to 2025.

In 2024 the company made an operating profit yet recorded a net loss of about KRW 28 billion, which points to a large impact from non-operating items. Net profit including non-controlling interests is a different figure, with a net loss of KRW 5.63 billion in 2025.

The company attributed the 2025 declines in revenue and operating income to weaker business at its subsidiary, while financial income growth and lower costs were cited for the narrower 2025 net loss.

Equity at year-end 2025 was KRW 306.6 billion, all attributable to controlling shareholders, with total liabilities of KRW 13.9 billion, and the debt ratio fell from 10.9% in 2024 to 4.5% in 2025.

Operating cash flow declined from KRW 17.3 billion in 2022 to KRW 1.66 billion in 2023, KRW 4.71 billion in 2024 and KRW 2.44 billion in 2025.

Quarterly revenue went from KRW 2.53 billion in the third quarter of 2025 to KRW 2.42 billion in the first quarter of 2026, then jumped to KRW 3.4 billion in the second quarter, up 40.5%, before settling at KRW 2.84 billion in the third quarter, down 16.5% sequentially but up 12.4% year on year.

Operating losses widened from KRW 409 million in the third quarter of 2025 to KRW 507 million and KRW 542 million, before the second quarter of 2026 turned to an operating profit of KRW 80.58 million; the third quarter returned to an operating loss of KRW 302 million.

Net profit attributable to controlling shareholders of KRW 46.1 billion in the second quarter and KRW 31.5 billion in the third quarter is far larger than these operating results, so the four-quarter total of KRW 71.1 billion is hard to read as operating strength.

05

Industry analysis

In domestic pharmaceutical distribution, competition among wholesalers has intensified, and revenue has been shrinking even though the company holds a high market share. The insulation business depends on the cycle of nuclear plant construction and project volume, so earnings move with the timing of orders.

As of the cumulative period through the third quarter of 2025, construction at Saeul Units 3 and 4 was ongoing but volume was below the prior year. Overseas, the push to export nuclear power plants has widened the prospects for entry into Poland and the Czech Republic.

A corporate information service, WISEreport, commented that a shipbuilding upturn and rising storage tank demand are expected to increase demand for FOAMGLAS insulation.

In competitive terms, insulation depends on winning overseas nuclear and shipbuilding projects, while pharmaceutical distribution is a contest over wholesale share, so the competitive logic of the two businesses differs.

Compared with listed peers in distribution and consumer goods, Aptocrom combines pharmaceutical wholesale with nuclear insulation, so a single industry average does not explain it well. The company appears to sit at a point where a domestic construction slowdown overlaps with hopes for overseas exports.

06

Outlook

The 20-to-1 free share consolidation decided on February 23, 2026 aims to offset accumulated deficits and improve the financial structure. According to the capital reduction disclosure, share capital falls from about KRW 110.4 billion to about KRW 5.5 billion, with a reduction ratio of 95% on common shares.

At the regular shareholder meeting on March 30, 2026, the main agenda items, including the capital reduction, were all approved.

From May 4, 2026, trading was suspended for an electronic registration change tied to share consolidation and division, and June 1, 2026 was disclosed as the planned listing date for the new shares.

The blockchain and virtual asset business purposes added to the articles of incorporation do not yet appear as numbers in the reported results. For insulation revenue to recover, construction volume must return first. Whether the overseas export projects turn into actual contracts will become clear through disclosures.

The next regular report, the 2026 annual report, will include fourth-quarter results and the breakdown of full-year non-operating items. Because the share count changed after the capital reduction, simple comparison with past per-share figures is difficult.

07

Valuation

PER
0.3×
PBR
0.1×
ROE
20.2%
EPS
₩5,368
BPS
₩29,699
Dividend per share
₩0

Valuation is best read on two bases, assets and earnings. On an asset basis, market capitalization sits far below year-end 2025 equity of KRW 306.6 billion. The price-to-book ratio is well under 1x, meaning the shares trade at a discount to net asset value, but that does not mean the assets are generating earnings.

On an earnings basis, only one of the last four quarters, the second quarter of 2026, posted an operating profit, so earnings multiples depend more on non-operating items than on operating income.

The earnings multiple based on the last four quarters, with net profit attributable to controlling shareholders totaling KRW 71.1 billion, looks low, but four quarters are too few to tell whether that profit is recurring.

The sequence from a turn to profit in 2023, a large net loss in 2024 and a return to an operating loss in 2025 means the earnings recovery has a short track record.

The cash dividend yield sits below the industry average, and because the share count changed after the 2026 capital reduction, past per-share figures cannot be compared directly.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Thick equity base and low debt

Equity at year-end 2025 was KRW 306.6 billion, all attributable to controlling shareholders, with total liabilities of KRW 13.9 billion and a debt ratio that fell from 10.9% in 2024 to 4.5% in 2025. The strength of the financial base despite losses is cited on the bullish side.

Asset size does not by itself mean profitability, so how far those assets convert into operating profit is the point to watch alongside it.

Signs of quarterly profit turnaround in 2026

Operating profit turned positive at KRW 80.58 million in the second quarter of 2026, when revenue rose to KRW 3.4 billion, up 40.5% from the prior quarter. Third-quarter revenue of KRW 2.84 billion was up 12.4% from a year earlier. A single operating profit at the operating level shows the potential for recovery. However, the third quarter returned to an operating loss of KRW 302 million.

Overseas nuclear entry and shipbuilding demand

The push to export nuclear plants has widened the possibility of entry into Poland and the Czech Republic. The corporate information service WISEreport noted that a shipbuilding upturn and rising storage tank demand are expected to lift demand for FOAMGLAS insulation.

If overseas projects turn into actual orders, they could offset part of the decline in domestic construction volume.

09

Bear factors

Sharp 2025 drop in revenue and operating income

Revenue in 2025 fell 40.2% to KRW 9.81 billion, and operating income turned into an operating loss of KRW 2.29 billion, with an operating margin of -23.3%. The company pointed to weaker business at its subsidiary.

In insulation, construction revenue declined after the completion of Shin Hanul Unit 2, and the construction volume needed for a revenue recovery has not clearly returned.

Intensifying competition in pharmaceutical wholesale

Competition among pharmaceutical wholesalers has intensified. The company held a high market share, yet its revenue declined. A shrinking top line despite a high share points to pressure on pricing or trading terms.

Because pharmaceuticals form the base of revenue, a contraction in this segment directly affects overall results.

Quarterly losses returning and non-recurring net profit

The third quarter of 2026 returned to an operating loss of KRW 302 million. Net profit attributable to controlling shareholders of KRW 46.1 billion in the second quarter and KRW 31.5 billion in the third quarter were far out of line with operating results.

Because the source of profit appears to lie outside operations, quarterly net income could swing sharply. In 2024 as well, a net loss of about KRW 28 billion appeared even with an operating profit.

10

Risk factors

Dependence on construction projects

The insulation business relies heavily on the timing and volume of nuclear construction. Even with Saeul Units 3 and 4 under construction, volume was below the prior year. Delays or fewer orders could cause revenue to fall again sharply. If overseas exports do not turn into contracts, this concentration remains in place.

Capital restructuring and trading changes

A 20-to-1 free share consolidation was decided, sharply reducing share capital. Trading in the shares was suspended on February 23, 2026, and a further suspension tied to an electronic registration change followed from May 4, 2026. As trading resumed with a changed share count and trading structure, price volatility could rise.

Credit rating and volatile non-operating results

Both KIS and NICE rate the company's bonds at B-, which is well below investment grade. A rating at this level can limit funding flexibility. The heavy dependence of net income on non-operating items also makes the results harder to interpret. Together, these two factors could make quarter-to-quarter financial assessment more volatile.

11

What to watch next

  1. Late March 2027

    The filing deadline for the 2026 annual report. The checkpoints are fourth-quarter results, full-year operating margin, whether insulation revenue recovered from its 2025 level, and which non-operating items account for the gap between net profit and operating income.

  2. Timing of fourth-quarter 2026 results disclosure (not fixed)

    The fourth quarter of 2026 needs a firm disclosure before the annual report. The items to confirm are whether the third-quarter operating loss of KRW 302 million continues and whether non-operating items again swing by large amounts.

  3. Not fixed (at the time of any order disclosure)

    Whether disclosures show contracts or participation in the Poland and Czech nuclear export projects. If overseas orders are confirmed, the next question is whether they can offset the fall in domestic construction volume.

12

Overall view

Aptocrom's core business has weakened, with 2025 revenue down 40.2% and a return to an operating loss, and quarterly results have diverged sharply in 2026.

An operating profit in the second quarter and an operating loss in the third appear side by side, and net profit attributable to controlling shareholders far exceeded operating scale, indicating a large non-operating effect.

On the balance sheet, year-end 2025 equity of KRW 306.6 billion and a 4.5% debt ratio form a thick financial base. The capital reduction and trading suspensions changed the share count and trading structure, so simple comparison with past per-share figures is difficult.

Insulation still depends on construction volume after the completion of Shin Hanul Unit 2, and overseas nuclear and shipbuilding demand is an upside factor that has not yet been confirmed by disclosed contracts. Pharmaceutical wholesale has shrunk amid intensifying competition.

The next checkpoints are the operating margin and the composition of non-operating items in the 2026 annual report, along with any disclosure of overseas orders.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.wisereport.co.kr
  2. m.news.nate.com
  3. comp.fnguide.com
  4. news.nate.com
  5. news.nate.com
  6. m.news.nate.com
  7. news.nate.com
  8. marketin.edaily.co.kr
  9. topstarnews.net
  10. tradingview.com
  11. judal.co.kr
  12. judal.co.kr
  13. tradingview.com
  14. judal.co.kr
  15. judal.co.kr
  16. judal.co.kr
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis